Statins, the inhibitors of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase for treating hyperlipidemia, were previously reported to reduce the risk of cardiovascular diseases [18]. Here, HMGCR is linked to hyperlipidemia.